Treace Medical Concepts Quarterly Balance Sheets Chart
Quarterly
|
Annual
Treace Medical Concepts Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||
| current assets | ||||||||||||||||||
| cash and cash equivalents | 8,052,000 | 13,372,000 | 11,350,000 | 12,110,000 | 18,181,000 | 9,334,000 | 12,982,000 | 7,278,000 | 12,035,000 | 29,613,000 | 19,473,000 | 88,546,000 | 101,533,000 | 98,483,000 | 105,833,000 | 109,459,000 | 119,621,000 | 16,218,000 |
| marketable securities, short-term | 61,237,000 | 62,717,000 | 64,327,000 | 70,689,000 | 76,865,000 | 100,672,000 | 110,216,000 | 114,885,000 | 127,444,000 | 141,049,000 | 61,779,000 | |||||||
| accounts receivable | 30,333,000 | 31,110,000 | 40,803,000 | 24,177,000 | 25,559,000 | 30,083,000 | 38,063,000 | 24,996,000 | 27,232,000 | 25,365,000 | 29,196,000 | 18,548,000 | 16,501,000 | 15,995,000 | 18,568,000 | 11,795,000 | 10,047,000 | 10,793,000 |
| inventories | 42,397,000 | 37,940,000 | 39,255,000 | 43,611,000 | 41,279,000 | 35,860,000 | 29,245,000 | 29,312,000 | 26,101,000 | 22,519,000 | 19,330,000 | 16,794,000 | 13,168,000 | 11,112,000 | 10,561,000 | 10,351,000 | 7,643,000 | 7,370,000 |
| prepaid expenses and other current assets | 5,583,000 | 4,298,000 | 5,667,000 | 7,015,000 | 9,668,000 | 11,448,000 | 7,853,000 | 10,671,000 | 5,284,000 | 4,587,000 | 3,624,000 | 4,014,000 | 3,995,000 | 1,723,000 | 3,010,000 | 3,760,000 | 3,512,000 | 2,072,000 |
| total current assets | 147,602,000 | 149,437,000 | 161,402,000 | 157,602,000 | 171,552,000 | 187,397,000 | 198,359,000 | 187,142,000 | 198,096,000 | 223,133,000 | 133,402,000 | 127,902,000 | 135,197,000 | 127,313,000 | 137,972,000 | 135,365,000 | 140,823,000 | 36,453,000 |
| property and equipment | 29,708,000 | 27,129,000 | 25,953,000 | 25,168,000 | 24,245,000 | 24,517,000 | 22,298,000 | 21,536,000 | 19,435,000 | 15,915,000 | 15,338,000 | 14,148,000 | 8,741,000 | 3,996,000 | 2,849,000 | 2,225,000 | 1,475,000 | 929,000 |
| intangible assets, net of accumulated amortization of 1,900 and 1,425 as of june 30, 2025 and december 31, 2024, respectively | 7,600,000 | |||||||||||||||||
| goodwill | 12,815,000 | 12,815,000 | 12,815,000 | 12,815,000 | 12,815,000 | 12,815,000 | 12,815,000 | 12,815,000 | 12,815,000 | |||||||||
| operating lease right-of-use assets | 8,042,000 | 8,241,000 | 8,442,000 | 8,569,000 | 8,775,000 | 9,064,000 | 9,264,000 | 9,459,000 | 9,651,000 | 9,907,000 | 10,138,000 | 14,247,000 | 14,650,000 | 15,069,000 | ||||
| other non-current assets | 676,000 | 387,000 | 407,000 | 458,000 | 146,000 | 146,000 | 146,000 | 146,000 | 146,000 | 215,000 | 146,000 | 146,000 | 134,000 | 134,000 | ||||
| total assets | 206,443,000 | 205,846,000 | 217,094,000 | 212,924,000 | 226,083,000 | 242,726,000 | 251,907,000 | 240,360,000 | 249,643,000 | 249,170,000 | 159,024,000 | 156,443,000 | 158,722,000 | 146,512,000 | 140,821,000 | 137,590,000 | 142,298,000 | 37,382,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||
| current liabilities | ||||||||||||||||||
| accounts payable | 19,959,000 | 13,223,000 | 10,522,000 | 18,649,000 | 18,073,000 | 21,149,000 | 11,835,000 | 8,680,000 | 8,146,000 | 5,076,000 | 8,668,000 | 7,881,000 | 3,099,000 | 3,448,000 | 4,056,000 | 2,442,000 | 2,921,000 | 1,269,000 |
| accrued liabilities | 6,192,000 | 6,008,000 | 7,197,000 | 8,098,000 | 13,730,000 | 15,155,000 | 10,458,000 | 8,936,000 | 7,072,000 | 7,971,000 | 6,216,000 | 5,189,000 | 4,809,000 | 3,552,000 | 4,518,000 | 2,824,000 | 1,957,000 | 2,821,000 |
| accrued commissions | 5,328,000 | 6,529,000 | 10,121,000 | 5,347,000 | 5,931,000 | 5,527,000 | 10,759,000 | 5,278,000 | 5,661,000 | 5,891,000 | 7,356,000 | 4,131,000 | 4,308,000 | 3,882,000 | 5,181,000 | 3,021,000 | 2,553,000 | 2,716,000 |
| accrued compensation | 7,064,000 | 5,190,000 | 6,575,000 | 5,598,000 | 6,192,000 | 4,196,000 | 7,549,000 | 5,070,000 | 5,368,000 | 3,300,000 | 7,666,000 | 5,049,000 | 4,038,000 | 4,060,000 | 4,455,000 | 2,436,000 | 2,434,000 | 1,782,000 |
| other liabilities | 3,357,000 | 2,230,000 | 510,000 | 571,000 | 520,000 | 1,022,000 | 4,432,000 | 5,190,000 | 3,775,000 | |||||||||
| total current liabilities | 41,900,000 | 33,180,000 | 34,925,000 | 38,263,000 | 44,446,000 | 47,049,000 | 45,033,000 | 33,154,000 | 30,022,000 | 23,296,000 | 30,245,000 | 22,580,000 | 16,637,000 | 15,377,000 | 18,210,000 | 10,723,000 | 9,865,000 | 8,588,000 |
| long-term debt | 53,454,000 | 53,380,000 | 53,306,000 | |||||||||||||||
| operating lease liabilities, net of current portion | 13,437,000 | 13,908,000 | 15,934,000 | 16,487,000 | 16,302,000 | 16,166,000 | 15,891,000 | 16,375,000 | 16,766,000 | 15,447,000 | 15,539,000 | 19,026,000 | 17,811,000 | 14,824,000 | ||||
| other long-term liabilities | 37,000 | 37,000 | 37,000 | 37,000 | 37,000 | 37,000 | 37,000 | 37,000 | 37,000 | 25,000 | ||||||||
| total liabilities | 108,828,000 | 100,505,000 | 104,202,000 | 108,018,000 | 113,942,000 | 116,335,000 | 113,969,000 | 102,500,000 | 99,684,000 | 91,553,000 | 98,495,000 | 94,242,000 | 87,010,000 | 59,694,000 | 47,748,000 | 40,217,000 | 39,387,000 | 38,066,000 |
| commitments and contingencies | ||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of june 30, 2025 and december 31, 2024; 0 shares issued as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||
| common stock | 63,000 | 63,000 | 62,000 | 62,000 | 62,000 | 62,000 | 62,000 | 62,000 | 62,000 | 61,000 | 55,000 | 46,000 | 46,000 | 46,000 | 45,000 | 45,000 | 45,000 | |
| additional paid-in capital | 321,508,000 | 311,815,000 | 303,004,000 | 294,392,000 | 286,484,000 | 279,433,000 | 271,973,000 | 265,912,000 | 260,561,000 | 255,786,000 | 145,221,000 | 142,463,000 | 139,841,000 | 137,713,000 | 134,933,000 | 132,614,000 | 131,734,000 | 15,136,000 |
| accumulated deficit | -223,310,000 | -205,912,000 | -189,990,000 | -189,489,000 | -174,129,000 | -152,923,000 | -134,247,000 | -127,966,000 | -110,445,000 | -98,174,000 | -84,720,000 | -80,308,000 | -68,175,000 | -50,941,000 | -41,905,000 | -35,286,000 | -28,868,000 | -23,785,000 |
| accumulated other comprehensive income | 50,000 | 57,000 | 97,000 | 191,000 | -26,000 | 69,000 | 163,000 | -148,000 | -219,000 | -56,000 | -27,000 | |||||||
| treasury stock | -696,000 | -682,000 | -281,000 | -250,000 | -250,000 | -250,000 | -13,000 | |||||||||||
| total stockholders’ equity | 97,615,000 | 105,341,000 | 112,892,000 | 104,906,000 | 112,141,000 | 126,391,000 | 137,938,000 | 137,860,000 | 149,959,000 | 157,617,000 | 60,529,000 | 62,201,000 | 71,712,000 | 86,818,000 | 93,073,000 | 97,373,000 | 102,911,000 | |
| total liabilities and stockholders’ equity | 206,443,000 | 205,846,000 | 217,094,000 | 212,924,000 | 226,083,000 | 242,726,000 | 251,907,000 | 240,360,000 | 249,643,000 | 249,170,000 | 159,024,000 | 156,443,000 | 158,722,000 | 146,512,000 | 140,821,000 | 137,590,000 | 142,298,000 | |
| intangible assets, net of accumulated amortization of 1,663 and 1,425 as of march 31, 2025 and december 31, 2024, respectively | 7,837,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of march 31, 2025 and december 31, 2024; 0 shares issued as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||
| intangible assets, net of accumulated amortization of 1,425 and 475 as of december 31, 2024 and december 31, 2023, respectively | 8,075,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of december 31, 2024 and december 31, 2023; 0 shares issued as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||
| intangible assets, net of accumulated amortization of 1,188 and 475 as of september 30, 2024 and december 31, 2023, respectively | 8,312,000 | |||||||||||||||||
| long-term debt, net of discount of 769 and 992 as of september 30, 2024 and december 31, 2023, respectively | 53,231,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of september 30, 2024 and december 31, 2023; 0 shares issued and outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||
| intangible assets, net of accumulated amortization of 950 and 475 as of june 30, 2024 and december 31, 2023, respectively | 8,550,000 | |||||||||||||||||
| long-term debt, net of discount of 843 and 992 as of june 30, 2024 and december 31, 2023, respectively | 53,157,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of june 30, 2024 and december 31, 2023; 0 shares issued and outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||
| intangible assets, net of accumulated amortization of 713 and 475 as of march 31, 2024 and december 31, 2023, respectively | 8,787,000 | |||||||||||||||||
| long-term debt, net of discount of 917 and 992 as of march 31, 2024 and december 31, 2023, respectively | 53,083,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of march 31, 2024 and december 31, 2023; 0 shares issued and outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||
| intangible assets, net of accumulated amortization of 475 and 0 as of december 31, 2023 and december 31, 2022, respectively | 9,025,000 | |||||||||||||||||
| long-term debt, net of discount of 992 and 1,289 as of december 31, 2023 and december 31, 2022, respectively | 53,008,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of december 31, 2023 and december 31, 2022; 0 shares issued and outstanding as of december 31, 2023 and december 31, 2022 | ||||||||||||||||||
| intangible assets, net of accumulated amortization of 238 and 0 as of september 30, 2023 and december 31, 2022, respectively | 9,262,000 | |||||||||||||||||
| long-term debt, net of discount of 1,066 and 1,289 as of september 30, 2023 and december 31, 2022, respectively | 52,934,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of september 30, 2023 and december 31, 2022; 0 shares issued and outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||
| intangible assets | 9,500,000 | |||||||||||||||||
| long-term debt, net of discount of 1,141 and 1,289 as of june 30, 2023 and december 31, 2022, respectively | 52,859,000 | |||||||||||||||||
| operating lease and other liabilities | 1,058,000 | |||||||||||||||||
| long-term debt, net of discount of 1,215 and 1,289 as of march 31, 2023 and december 31, 2022, respectively | 52,785,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of march 31, 2023 and december 31, 2022; 0 shares issued and outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||
| operating lease liabilities | 339,000 | 330,000 | 383,000 | 435,000 | ||||||||||||||
| derivative liability on term loan | 83,000 | 173,000 | 173,000 | 245,000 | 245,000 | |||||||||||||
| long-term debt, net of discount of 1,289 and 635 as of december 31, 2022 and 2021, respectively | 52,711,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of december 31, 2022 and december 31, 2021; 0 shares issued and outstanding as of december 31, 2022 and december 31, 2021 | ||||||||||||||||||
| long-term debt, net of discount of 1,364 and 635 as of september 30, 2022 and december 31, 2021, respectively | 52,636,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of september 30, 2022 and december 31, 2021; 0 shares issued and outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||
| long-term debt, net of discount of 1,438 and 635 as of june 30, 2022 and december 31, 2021, respectively | 52,562,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of june 30, 2022 and december 31, 2021; 0 shares issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||
| long-term debt, net of discount of 590 and 635 as of march 31, 2022 and december 31, 2021, respectively | 29,410,000 | |||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized as of march 31, 2022 and december 31, 2021; 0 shares issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||
| short-term debt | ||||||||||||||||||
| long-term debt, net of discount of 635 and 811 as of december 31, 2021 and 2020, respectively | 29,365,000 | |||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 shares authorized and 0 shares issued and outstanding as of december 31, 2021; 6,687,500 shares authorized and 6,687,475 shares issued and outstanding as of december 31, 2020; liquidation value of 0 and 8,000 as of december 31, 2021 and 2020, respectively | ||||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized; 0 shares issued and outstanding as of december 31, 2021; 0 shares authorized, issued and outstanding as of december 31, 2020 | ||||||||||||||||||
| common stock class b, 0.001 par value, 0 shares authorized, issued and outstanding as of december 31, 2021; 1,000,000 shares authorized and 0 shares issued and outstanding as of december 31, 2020 | ||||||||||||||||||
| long-term debt, net of discount of 679 and 811 as of september 30, 2021 and december 31, 2020, respectively | 29,321,000 | |||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 shares authorized and 0 shares issued and outstanding as of september 30, 2021; 6,687,500 shares authorized and 6,687,475 shares issued and outstanding as of december 31, 2020, respectively; liquidation value of 0 and 8,000 as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized; 0 shares issued and outstanding as of september 30, 2021; 0 shares authorized, issued and outstanding as of december 31, 2020 | ||||||||||||||||||
| common stock class b, 0.001 par value, 0 shares authorized, issued and outstanding as of september 30, 2021; 1,000,000 shares authorized and 0 shares issued and outstanding as of december 31, 2020 | ||||||||||||||||||
| long-term debt, net of discount of 723 and 811 as of june 30, 2021 and december 31, 2020, respectively | 29,277,000 | |||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 0 shares authorized and 0 shares issued and outstanding as of june 30, 2021; 6,687,500 shares authorized and 6,687,475 shares issued and outstanding as of december 31, 2020, respectively; liquidation value of 0 and 8,000 as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| preferred stock, 0.001 par value, 5,000,000 shares authorized; 0 shares issued and outstanding as of june 30, 2021; 0 shares authorized, issued and outstanding as of december 31, 2020 | ||||||||||||||||||
| common stock class b, 0.001 par value, 0 shares authorized, issued and outstanding as of june 30, 2021; 1,000,000 shares authorized and 0 shares issued and outstanding as of december 31, 2020 | ||||||||||||||||||
| liabilities, and stockholders’ equity | ||||||||||||||||||
| long-term debt, net of discount of 767 and 811 as of march 31, 2021 and december 31, 2020, respectively | 29,233,000 | |||||||||||||||||
| stockholders’ (deficit) equity | ||||||||||||||||||
| series a preferred stock, 0.001 par value, 6,687,500 shares authorized; 6,687,475 shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively; liquidation value of 8,000 as of march 31, 2021 and december 31, 2020, respectively | 7,935,000 | |||||||||||||||||
| common stock class a, 0.001 par value, 66,875,000 shares authorized as of march 31, 2021 and december 31, 2020, respectively; 38,057,416 shares and 37,366,865 issued and outstanding as of march 31, 2021 and december 31, 2020, respectively | 30,000 | |||||||||||||||||
| common stock class b, 0.001 par value, 1,000,000 shares authorized as of march 31, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||
| total stockholders’ (deficit) equity | -684,000 | |||||||||||||||||
| total liabilities, and stockholders’ equity | 37,382,000 |
We provide you with 20 years of balance sheets for Treace Medical Concepts stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Treace Medical Concepts. Explore the full financial landscape of Treace Medical Concepts stock with our expertly curated balance sheets.
The information provided in this report about Treace Medical Concepts stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.